@phdthesis{Fuhrmann2017,
  author    = {Julia Fuhrmann},
  title     = {Technical considerations on the NOD/SCID model for the study of anti-CD36 antibodies},
  journal    = {Betrachtung der Methoden des NOD/SCID Modells zur Untersuchung von anti-CD36 Antik{\"o}rpern},
  url       = {https://nbn-resolving.org/urn:nbn:de:gbv:9-opus-22792},
  pages     = {71},
  year      = {2017},
  abstract  = {Since its introduction in 2006, the NOD/scid mouse model has greatly contributed to the understanding of the pathomechanisms of antibody-mediated thrombocytopenia. This progress has however been hampered by inter-laboratory differences. With this work, we make several suggestions to minimise these differences: We suggest that human platelets (blood group 0) be injected into the mice (age- and sex-matched, 8-16 weeks) via the tail vein. For antibody injection, scientists may choose between intraperitoneal and tail vein injection, each of which has strengths and drawbacks. In case of low antibody titer or low avidity antibodies, preincubation of the platelets with the patient serum prior to injection promotes platelet elimination where standard protocols fail. For subsequent sample preparation, we found that newly-launched ready-to-use kits present a good alternative to classical density gradient centrifugation by reducing man-hours and turnover time without affecting the quality of flow cytometry analysis. In a second part, we used the revised mouse model to study anti-CD36 mediated thrombocytopenia in vivo. Anti-CD36 antibodies have been suggested as frequent case for FNAIT in Asia. The mechanisms behind this remain partly unclear. After injecting anti-CD36 monoclonal antibody or anti-CD36 patient immunoglobulin into the system, circulating human platelets were rapidly cleared. Interestingly, the polyclonal patient immunoglobulins used were not uniform in their anti-platelet reactivity. On further examination, we found that the anti-CD36 antibodies induce platelet activation and aggregation, which we were able to inhibit by the addition of an Fcγ-receptor blocking agent. This suggests a possible role for Fcγ-receptor in the activation and elimination process. As our results from the experiments on the role of complement in the elimination process are however ambiguous, further studies are needed. The clinical relevance of anti-CD36 antibody-mediated platelet activation and aggregation for the high abortion rates in affected women has yet to be evaluated.},
  language  = {en}
}